Sotera Health Company (SHC)

On our desk, the disconnect between Sotera Health's fundamental operational execution and its muted stock response is striking. Q2 2026 net income spiked to $54 million from just $8 million year-over-year, and management raised full-year guidance across the board with revenue expected to land between $1.236 billion and $1.254 billion. Yet, the stock barely moved, slipping 0.3% to $18.86. The market is clearly baking in a discount due to the lingering legal risks mentioned across financial commentary. While trailing earnings have grown sharply and adjusted EPS rose 30% to $0.26, investors are wrestling with a 32.9x P/E multiple and questioning the durability of this profitability edge against the persistent shadow of litigation.

Watching the fundamental drivers from a macro perspective, SHC's second-quarter outperformance was remarkably broad-based. Sterigenics revenue hit $212 million supported by 7% constant currency growth, a stable demand environment, and 4.3% favorable pricing and volume, while Nordion contributed $49 million. Furthermore, capital expenditures are scaling up to an expected $200 million to $225 million for 2026 as the company actively expands capacity, upgrades facilities, and benefits from a major customer outsourcing shift. Net leverage has successfully declined to three times, providing a more stable balance sheet even as the company funds these strategic investments.

From our technical and clinical infrastructure standpoint, Sotera Health’s mission-critical positioning in sterilization and medical isotope segments is exceptionally entrenched. The integration of new X-ray capacity and sustained high-margin operations across Sterigenics and Nordion validate the underlying demand environment. However, when evaluating the operational risk profile, the heavy reliance on capital investments for capacity expansion—pushing full-year CapEx up to $225 million—means execution risk on facility upgrades remains a critical metric to monitor alongside constant currency revenue growth rates hovering around 8%.